Loading workspace…
signed outSign in
Every requirement in bioskepsis-insights-user-requirements-v1.1.md, with the verdict the document’s own rules force. No requirement now carries the verdict BLOCKED. Each row carries both halves of its account, what is buildable and what is still held, and names the decisions that released it. A requirement answered the other way is DROPPED, and that is the one verdict nobody can go and change.
Showing the requirements whose account names OQ-40. Of the 18 shown, its answer released 18.
| ID | Verdict | Basis | What that means |
|---|---|---|---|
FR-TREND-05 | BUILD | stated | All of it, under the two minimums and the anonymity the answers set. A field signal is shown when at least 8 distinct people stand behind it (OQ-14) and, where it comes from OncoSkepsis, at least 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12). Counts are rounded to the nearest 5. Nobody is named: a pharma user sees an anonymous card, and an identity is revealed only when the expert or clinician accepts a contact request, which is stored as a consent record naming the company and the wording shown (OQ-05, OQ-42). Still held. Nothing. Below either minimum there is nothing to show, and the view says so, naming the minimum rather than rendering an empty result that reads as a quiet field. |
FR-ALERT-01 | BUILD | research | All of it, on the channels the answer names: a weekly email digest per user, and alerts written into the customer's CRM as tasks, for Veeva Vault CRM, Salesforce Life Sciences Cloud and IQVIA OCE (OQ-22, OQ-26). Subscriptions were already buildable; what was missing was where an alert goes and how often, and both are now stated rather than chosen here. Still held. Nothing. Every alert carries the same suppression as the view it came from: the 8-person minimum, the 3-institution minimum with the dominance check, counts rounded to 5, and nobody named without an accepted contact request (OQ-14, OQ-40, OQ-05). An alert is a delivery channel, not an exemption. |
X-01 | BUILD | inference | The cancer type named in a question, coded with OncoTree, whose code list version is stored on every signal (OQ-44). Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
X-02 | BUILD | inference | The gene named in a question, as an HGNC symbol (OQ-44), confirmed on 18/09/2026. Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
X-03 | BUILD | inference | The tumour variant named in a question, in HGVS notation with a ClinGen Allele Registry ID (OQ-44). A variant-level signal is shown only above both minimums and rolls up to the gene otherwise (OQ-41), which is the whole of the re-identification control here. Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
X-04 | BUILD | inference | The drug, drug class or mechanism named in a question, coded with ChEMBL (OQ-44). ChEMBL is CC BY-SA 3.0, so anything derived from it that this product shares travels under the same licence. Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
X-05 | BUILD | inference | The question type, from the six OncoSkepsis functions: tumour-board case, variant interpretation, tumour-board brief, country-specific literature, reimbursement dossier and clinical-trial search (OQ-45, NP-13). Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
X-06 | BUILD | inference | The country of the contributing clinician, which is what makes a country facet possible without a named person behind it. Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
X-08 | BUILD | inference | The contributing clinician's professional role, from the list OQ-10 states, confirmed on 18/09/2026. Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
X-09 | BUILD | inference | The evidence status of the answer, as contested evidence or thin evidence, confirmed on 18/09/2026. These two flags are what the research-gap view is built from (NP-07), which is why the field exists at all. Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
X-10 | BUILD | inference | The counts themselves: questions, distinct contributing clinicians and distinct contributing institutions, which are what the two minimums are measured against. Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
X-11 | BUILD | inference | The change in question counts between two periods, confirmed on 18/09/2026 and governed by NP-10. Comparing two tables can reveal a small number even when each table separately meets the threshold, so the differencing check stands in front of every export and API answer, and an in-app view shows a warning instead. Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
X-14 | BUILD | inference | Reimbursement-dossier requests, as group counts by drug and country and never per hospital (OQ-45). Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
X-15 | BUILD | inference | Clinical-trial search activity, as group counts by cancer type and country (OQ-45). The search that produces it is built inside OncoSkepsis on ClinicalTrials.gov and the EU trial portal (NP-13). Still held. Nothing. Shown only above both minimums: 8 distinct contributing people (OQ-14) and 3 distinct institutions with the 5 percent dominance check (OQ-40, NP-12), with counts rounded to the nearest 5 and the differencing check refusing an export or API answer whose comparison could reveal a hidden count (NP-10). |
NEVER-03 | BUILD | inference | All of it, confirmed by OQ-40: no institution name and no tumour-board name is attached to any clinical signal. What reaches this product is a count of distinct institutions, which is what the 3-institution minimum and the dominance check are measured against. Still held. Nothing. A count is not a name, and the dominance check exists precisely so that a count cannot be read back as one. |
XFER-09 | BUILD | inference | All of it, confirmed by OQ-40, which supplies both numbers: an OncoSkepsis signal is shown only when at least 3 institutions stand behind it and no single institution dominates, where dominance is the count minus the two largest institutional contributions falling under 5 percent of the largest (NP-12). The 8-person minimum of OQ-14 applies on top. Still held. Nothing. p is held in configuration, so a site that needs a stricter rule sets one rather than patching a literal. |
XFER-10 | BUILD | research | All of it, on the strength NP-10 chose: a comparison that could reveal a hidden count blocks the export or the API answer outright, and an in-app view shows a warning instead. The check runs before every export and every API answer rather than at the point the data is stored. Still held. Nothing. The asymmetry is deliberate: an export leaves the building and cannot be recalled, while an in-app view is read by a signed-in user whose access is logged. |
XFER-12 | BUILD | inference | All of it, confirmed by OQ-40. The institution minimum applies in every view, export, alert and API answer, and NP-01 adds the launch consequence: until a third hospital joins, nothing from OncoSkepsis is releasable, and the view says so. Still held. Nothing. |